B. Riley Securities Reiterates Buy on Altimmune, Maintains $20 Price Target

Altimmune Inc -6.31% Post

Altimmune Inc

ALT

5.20

5.24

-6.31%

+0.77% Post

B. Riley Securities analyst Mayank Mamtani reiterates Altimmune (NASDAQ: ALT) with a Buy and maintains $20 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via